267 related articles for article (PubMed ID: 23123399)
1. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
Cho CH; Lee HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
[TBL] [Abstract][Full Text] [Related]
2. Free radicals, antioxidant defense systems, and schizophrenia.
Wu JQ; Kosten TR; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():200-6. PubMed ID: 23470289
[TBL] [Abstract][Full Text] [Related]
3. Genetics of tardive dyskinesia.
Lee HJ; Kang SG
Int Rev Neurobiol; 2011; 98():231-64. PubMed ID: 21907090
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.
Zai CC; Tiwari AK; Basile V; de Luca V; Müller DJ; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):50-6. PubMed ID: 19778569
[TBL] [Abstract][Full Text] [Related]
6. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].
Gałecki P; Pietras T; Szemraj J
Psychiatr Pol; 2006; 40(5):937-48. PubMed ID: 17217237
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and therapeutic implications in psychiatric disorders.
Zhang XY; Yao JK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():197-9. PubMed ID: 23523744
[TBL] [Abstract][Full Text] [Related]
8. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.
Hitzeroth A; Niehaus DJ; Koen L; Botes WC; Deleuze JF; Warnich L
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):664-72. PubMed ID: 17291655
[TBL] [Abstract][Full Text] [Related]
9. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
[TBL] [Abstract][Full Text] [Related]
10. Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia.
Wu JQ; Chen DC; Tan YL; Soares JC; Zhang XY
Hum Psychopharmacol; 2015 Jan; 30(1):57-63. PubMed ID: 25572310
[TBL] [Abstract][Full Text] [Related]
11. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients.
Kang SG; Choi JE; An H; Park YM; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Joe SH; Jung IK; Kim L; Lee MS
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1844-7. PubMed ID: 18790709
[TBL] [Abstract][Full Text] [Related]
12. Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia.
Pae CU
Psychiatry Res; 2008 Dec; 161(3):336-8. PubMed ID: 18977034
[TBL] [Abstract][Full Text] [Related]
13. [Pro- and antioxidant processes in schizophrenics with tardive dyskinesia].
Gałecki P; Pietras T; Florkowki A
Psychiatr Pol; 2005; 39(6):1131-41. PubMed ID: 16526180
[TBL] [Abstract][Full Text] [Related]
14. Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity.
Wu JQ; Chen DC; Tan YL; Tan SP; Wang ZR; Xiu MH; Yang FD; Zhang XY
Schizophr Res; 2014 Jan; 152(1):210-6. PubMed ID: 24325977
[TBL] [Abstract][Full Text] [Related]
15. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia.
Shinkai T; De Luca V; Hwang R; Matsumoto C; Hori H; Ohmori O; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Nakamura J; Kennedy JL
Neurosci Lett; 2005 Nov; 388(2):116-20. PubMed ID: 16039055
[TBL] [Abstract][Full Text] [Related]
16. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
17. B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Macêdo DS; Oliveira GV; Gomes PX; Araújo FY; Souza CM; Vasconcelos SM; Viana GS; Sousa FC; Carvalho AF
Behav Pharmacol; 2011 Oct; 22(7):674-80. PubMed ID: 21918383
[TBL] [Abstract][Full Text] [Related]
18. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.
Zhang Z; Zhang X; Hou G; Sha W; Reynolds GP
J Psychiatr Res; 2002; 36(5):317-24. PubMed ID: 12127599
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia: Who gets it and why.
Frei K
Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
[TBL] [Abstract][Full Text] [Related]
20. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia.
Zhang XY; Tan YL; Zhou DF; Cao LY; Wu GY; Haile CN; Kosten TA; Kosten TR
J Clin Psychiatry; 2007 May; 68(5):754-60. PubMed ID: 17503985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
